Cimetidine in the treatment of porphyria cutanea tarda. 1996

Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
Second Department of Internal Medicine, Tottori University School of Medicine, Yonago.

The efficacy of the H2 receptor antagonist, cimetidine, in the treatment of a patient with porphyria cutanea tarda (PCT) was evaluated. After administration of cimetidine for 2 weeks, urinary excretion of uroporphyrin (UP) and coproporphyrin (CP) was significantly decreased. Urinary porphyrin levels remained low even after the cessation of cimetidine for 1 week. Although the readministration of cimetidine did not decrease porphyrin excretion, skin lesions were markedly improved, and serum gamma-glutamyl transpeptidase (GGT), aminotransferases and serum ferritin decreased to the normal range. These results suggest that, in addition to efficacy in the treatment of acute intermittent porphyria (AIP) and erythropoietic protoporphyria (EPP), cimetidine is effective in the treatment of PCT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011166 Porphyrins A group of compounds containing the porphin structure, four pyrrole rings connected by methine bridges in a cyclic configuration to which a variety of side chains are attached. The nature of the side chain is indicated by a prefix, as uroporphyrin, hematoporphyrin, etc. The porphyrins, in combination with iron, form the heme component in biologically significant compounds such as hemoglobin and myoglobin. Porphyrin
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017119 Porphyria Cutanea Tarda An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.

Related Publications

Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
July 2010, The Journal of dermatology,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
November 1970, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
January 1987, The British journal of dermatology,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
October 1963, Vestnik dermatologii i venerologii,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
January 1998, Skin pharmacology and applied skin physiology,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
July 1976, The British journal of dermatology,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
September 1970, Archives of dermatology,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
January 1972, Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
May 1976, Nederlands tijdschrift voor geneeskunde,
Y Horie, and K Tanaka, and J Okano, and N Ohgi, and H Kawasaki, and S Yamamoto, and M Kondo, and S Sassa
October 2001, Annales de dermatologie et de venereologie,
Copied contents to your clipboard!